Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 7
Submit an article Journal homepage
768
Views
18
CrossRef citations to date
0
Altmetric
Original Article: Clinical

The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia

Masa LasicaDepartment of Clinical Hematology, Austin Hospital, Heidelberg, Australia;
,
Abbey WillcoxDepartment of Clinical Hematology, Austin Hospital, Heidelberg, Australia; ;Australian Centre for Blood Disease, Monash University, Melbourne, Australia; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-9343-542X
ORCID Icon,
Kate BurburyPeter MacCallum Cancer Centre, East Melbourne, Australia;
,
David M. RossBedford Park, Flinders University and Medical Centre, AdelaideAustralia; ORCID Iconhttp://orcid.org/0000-0001-7171-2935
ORCID Icon,
Susan BranfordCentre for Cancer Biology, an alliance between SA Pathology and University of South Australia, Adelaide, Australia;
,
Jason ButlerRoyal Brisbane and Women’s Hospital, Brisbane, Australia;
,
Robin FilshieSt Vincent’s Hospital, Fitzroy, Australia;
,
Henry JanuszewiczPeter MacCallum Cancer Centre, East Melbourne, Australia;
,
David JoskeSir Charles Gairdner Hospital, Nedlands, Australia;
,
Anthony MillsRamsay Specialist Centre, Greenslopes Private Hospital, Greenslopes, Australia;
,
David SimpsonNorth Shore Hospital, Waitemata District Health Board, Auckland, New Zealand;
,
Constantine TamPeter MacCallum Cancer Centre, East Melbourne, Australia;
,
Kerry TaylorIcon Cancer Care, Mater Medical Centre, South Brisbane, Australia;
,
Anne-Marie WatsonLiverpool Hospital, Liverpool, Australia
,
Max WolfPeter MacCallum Cancer Centre, East Melbourne, Australia;
&
Andrew GriggDepartment of Clinical Hematology, Austin Hospital, Heidelberg, Australia;
show all
Pages 1796-1802 | Received 27 Apr 2018, Accepted 14 Nov 2018, Published online: 11 Jan 2019

References

  • Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872–884.
  • Hoglund M, Sandin F, Simonsson B. Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol. 2015;Suppl2:S241–S247.
  • Abruzzese E, Trawinska MM, Perrotti AP, et al. Tyrosine kinase inhibitors and pregnancy. Mediterr J Hematol Infect Dis. 2014;6:2014028.
  • Hochhaus A, Masszi T, Giles FJ, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31:1525–1531.
  • Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029–1035.
  • Richter J, Mahon FX, Guilhot J, et al. Stopping tyrosine kinase inhibitors in a very large cohort of European chronic myeloid leukemia patients: results of the EURO-SKI trial. Haematologica. 2016;101:22–23.
  • Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122:515–522.
  • Imagawa J, Tanaka H, Okada M, et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol. 2015;2:e528–e535.
  • Gynaecologists RCoOa. Late intrauterine fetal death and stillbirth. Green-top Guideline No. 55. October 2010.
  • Abruzzese E, Trawinska MM, de Fabritiis P, et al. Management of pregnant chronic myeloid leukemia patients. Exper Rev Hematol. 2016;9:781–791.
  • Bhandari A, Rolen K, Shah BK. Management of chronic myelogenous leukemia in pregnancy. Anticancer Res. 2015;35:1–11.
  • Gynaecologist RCoOa. The investigation and treatment of couples with recurrent first-trimester and second-trimester miscarriage. Green-top Guideline no. 17. April 2011.
  • Berman E, Druker BJ, Oncology RBJOC. Chronic myelogenous leukemia: pregnancy in the era of stopping tyrosine kinase inhibitor therapy. J Clin Oncol. 2018.
  • Ross DM, Hughes TP. How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia. Br J Haematol. 2014;166:3–11.
  • Garderet L, Santacruz R, Barbu V, et al. Two successful pregnancies in a chronic myeloid leukemia patient treated with imatinib. Haematologica. 2007;92:e9–10.
  • Sora F, De Matteis S, Bajer J, et al. Persistence of molecular remission throughout pregnancy in CML after imatinib. Leukemia Res. 2009;33:e6–e7.
  • [Internet] PaCMID. Symonston (ACT): therapeutic goods administration, Commonwealth of Australia; 2014. [cited 2017 July 21].
  • Product and consumer medicine information documents [Internet]. Symonston (ACT): therapeutic goods administration, Commonwealth of Australia; 2017. [cited 2017 July 21].
  • Pye SM, Cortes J, Ault P, et al. The effects of imatinib on pregnancy outcome. Blood. 2008;111:5505–5508.
  • Russell MA, Carpenter MW, Akhtar MS, et al. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk. J Perinatol. 2007;27:241–243.
  • Cortes JE, Abruzzese E, Chelysheva E, et al. The impact of dasatinib on pregnancy outcomes. Am J Hematol. 2015;90:1111–1115.
  • Conchon M, Sanabani SS, Bendit I, et al. Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: case study. J Hematol Oncol. 2009;2:42.
  • Etienne G, Milpied B, Rea D, et al. Guidelines for the management of nilotinib (Tasigna)-induced side effects in chronic myelogenous leukemia: recommendations of French Intergroup of CML (Fi-LMC group). Bulletin du Cancer. 2010;97:997–1009.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.